Brought to you by 
Pulmonx raises $32mm through its Series C venture round
Feb 2010
Executive Summary
Two years after withdrawing its IPO, Pulmonx (devices to diagnose and treat pulmonary disorders) has raised $32mm through its Series C venture round. New backers HealthCap and Kleiner Perkins Caufield & Byers, which co-led the financing and each contribute a board member, were joined by current shareholders DeNovo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners, and Posco BioVentures and nine undisclosed investors. The company is preparing for the commercial launch of its Chartis pulmonary assessment system and Zephyr endobronchial valve for emphysema.
Deal Industry
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com